This monthly feature will help readers keep current on new drugs, new indications, dosage forms, and safety-related changes in labeling or use. Efforts have been made to ensure the accuracy of this information; however, if there are any questions, please let me know at bakerdan@wsu.edu.
Indication:
Adjunctive therapy to diet to: reduce elevated total-C, LDL-C, Apo B, TG, and non-HDL-C and to increase HDL-C in patients with primary (heterozygous familial and nonfamilial) hyperlipidemia or mixed hyperlipidemia. reduce elevated total-C and LDL-C in patients with homozygous familial hypercholesterolemia (HoFH), as an adjunct to other lipid-lowering treatments. 
Mechanism of action:
Ezetimibe reduces blood cholesterol by inhibiting the absorption of cholesterol by the small intestine and atorvastatin by inhibiting HMG-CoA reductase and cholesterol synthesis in the liver and by increasing the number of hepatic LDL receptors on the cell-surface to enhance uptake and catabolism of LDL; atorvastatin also reduces LDL production and the number of LDL particles. 
CONTRAINDICATIONS
Candesartan is contraindicated in patients who are hypersensitive to candesartan. Do not administer aliskiren with candesartan in patients with diabetes.
WARNINGS AND PRECAUTIONS Hypotension
Candesartan can cause symptomatic hypotension. Symptomatic hypotension is most likely to occur in patients who have been volume and/or salt depleted as a result of prolonged diuretic therapy, dietary salt restriction, dialysis, diarrhea, or vomiting.
Impaired Renal Function
In the CHARM-Added program, where candesartan or placebo was given in addition to ACE inhibitors, the incidence of abnormal renal function (eg, creatinine increase) was 15% in patients treated with candesartan versus 9% in patients treated with placebo. Hyperkalemia
In the CHARM-Added program where candesartan or placebo was given in addition to ACE inhibitors, the incidence of hyperkalemia was 9.5% in patients treated with candesartan versus 3.5% in patients treated with placebo.
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